Generic Name and Formulations:
Mometasone furoate (as furoate monohydrate) 50mcg/spray; aqueous nasal spray.
Merck & Co., Inc.
Indications for NASONEX:
Treatment of seasonal and perennial allergic rhinitis symptoms in patients ≥2yrs of age. Prophylaxis of seasonal allergic rhinitis symptoms in patients ≥12yrs of age. Nasal polyps.
Allergic rhinitis: 2 sprays in each nostril once daily; prophylaxis: begin 2–4 weeks prior to anticipated start of pollen season. Nasal polyps: ≥18yrs: 2 sprays in each nostril 1–2 times daily.
Allergic rhinitis: <2yrs: not established. 2–11yrs: 1 spray in each nostril once daily. Nasal polyps: <18yrs: not established.
Maintain regular regimen. Respiratory tract tuberculosis. Infections (eg, ocular herpes simplex). If exposed to measles or chickenpox, consider anti-infective prophylactic therapy. If adrenal insufficiency exists following systemic corticosteroid therapy, replacement with topical corticosteroids may exacerbate symptoms of adrenal insufficiency (eg, depression). Monitor for growth suppression in children. Monitor for hypercorticism and HPA axis suppression (if occur discontinue gradually), and candida infection or other nasal mucosal changes. Glaucoma and/or cataracts. Discontinue if nasopharyngeal candida infection occurs. Avoid eyes. Pregnancy (Cat.C). Nursing mothers.
Caution when concomitant ketoconazole (long-term) and other strong CYP3A4 inhibitors (eg, ritonavir, cobicistat-containing products, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin); monitor.
Headache, viral infection, pharyngitis, epistaxis, cough, upper respiratory tract infections, pain, sinusitis, reduced growth velocity in children; rare: nasal ulcers.
Spray—17g (120 sprays)
Clinical Pain Advisor Articles
- Analyzing Coverage of Nonpharmacologic Treatments for Low Back Pain
- Smartphone App Helps Evaluate Catastrophizing in Chronic Pain
- Predicting the Magnitude of Placebo Analgesia in Chronic Pain
- Dsuvia Gains FDA Approval: We Want to Hear Your Thoughts
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Seven-Item Pain Intensity Measure Reliable in Individuals With Dementia
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Dozens of Medical Groups Join Forces to Improve Diagnoses
- FDA Grants Non-Opioid Analgesic VVZ-149 Fast Track Status
- Little to No Association Found Between Physician Performance and Medical School Ranking